Mark Rumbak
Pulmonary Disease · Tampa, FLNPI 1609967058
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $457,224 of the $528,271 with a category attached, or 86.6%. 26 manufacturers reported payments, led by GSK at 35.2% of the total. Reporting peaked in 2019 at $382,134 and has fallen 99.2% since, to $3,000 in 2021. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $1112.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$186K
- Mallinckrodt Enterprises LLC$94K
- United Therapeutics Corporation$57K
- Mallinckrodt Hospital Products Inc.$38K
- Genentech USA, Inc.$34K
- Insmed, Inc.$33K
- plus $86K from 20 others
What the payments were for
- Consulting fees$20,0604%
- Speaking & faculty fees$457,22487%
- Grants$3,0001%
- Travel & lodging$34,9937%
- Food & beverage$12,9872%
- Education$40%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 132 | $185,966 |
| Mallinckrodt Enterprises LLC | 53 | $94,499 |
| United Therapeutics Corporation | 52 | $56,897 |
| Mallinckrodt Hospital Products Inc. | 12 | $37,680 |
| Genentech USA, Inc. | 42 | $34,195 |
| Insmed, Inc. | 41 | $32,891 |
| Boehringer Ingelheim | 22 | $24,032 |
| Johnson & Johnson(2 entities) | 24 | $19,403 |
| Mylan Specialty L.p. | 13 | $10,304 |
| Actelion Pharmaceuticals US, Inc. | 22 | $9,523 |
| Sunovion Pharmaceuticals Inc. | 17 | $8,282 |
| Bayer | 6 | $5,087 |
| Genentech, Inc. | 1 | $3,000 |
| Intuitive Surgical | 10 | $2,267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,800 |
| Covidien LP | 3 | $731 |
| Viiv Healthcare Company | 1 | $600 |
| Tetraphase Pharmaceuticals, Inc. | 10 | $459 |
| La Jolla Pharmaceutical Company | 2 | $202 |
| AstraZeneca | 2 | $126 |
| Pinnacle Biologics, Inc | 1 | $113 |
| Auris Health, Inc. | 1 | $104 |
| Gilead | 3 | $50 |
| KARL Storz Endoscopy-america | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$149,714
- ACTHAR$129,211
- REMODULIN$37,811
- TYVASO$37,811
- ORENITRAM$33,253
- ANORO$29,405
- Esbriet$28,334
- Arikayce$22,512
- XARELTO$18,216
- NONE$16,683
- OFEV$11,761
- Yupelri$10,178
- LONHALA MAGNAIR$7,930
- UPTRAVI$6,395
- Adempas$5,010
- ANORO ELLIPTA$3,600
- Da Vinci Surgical System$2,041
- MONARCH$1,084
- OPSUMIT$760
- superDimension$694
How this compares
$528,271 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tampa
- Ricardo Restrepo-JaramilloTampa$555K
- Domenick ReinaTampa$469K
- Michael AlvarezTampa$202K
- Nirav PatelTampa$105K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.